- 1 Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19
- 2 patients
- 3 Beatriz Olea<sup>1</sup>, Eliseo Albert<sup>1</sup>, Ignacio Torres<sup>1</sup>, Paula Amat<sup>2</sup>, María José Remigia<sup>2</sup>,
- 4 Roberto Gozalbo-Rovira<sup>3</sup>, Jesús Rodríguez-Díaz<sup>3</sup>, Javier Buesa<sup>1,3</sup>, María Luisa Blasco<sup>4</sup>,
- 5 Josep Redón<sup>5,6</sup>, Jaime Signes-Costa<sup>7</sup> and David Navarro<sup>1,3\*</sup>
- 6 <sup>1</sup>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 7 Valencia, Spain.
- 8 <sup>2</sup>Hematology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 9 Valencia, Spain.
- 10 <sup>3</sup>Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 11 Spain.
- 12 <sup>4</sup>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research
- 13 Institute, Valencia, Spain.
- 14 <sup>5</sup>Internal Medicine Department, Clinic University Hospital, INCLIVA Health Research
- 15 Institute, Valencia, Spain.
- <sup>6</sup>Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
- <sup>17</sup>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 18 Valencia, Spain

25

- 20 \*Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 21 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 22 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
- 23 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- 24 david.navarro@uv.es.

**ABSTRACT** 

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

**Objectives:** There is an imperative need to determine the durability of adaptive immunity to SARS-CoV-2. We enumerated SARS-CoV-2-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells targeting S1 and M proteins and measured RBD-specific serum IgG over a period of 2-6 months after symptoms onset in a cohort of subjects who had recovered from severe clinical forms of COVID-19. **Methods:** We recruited 58 patients (38 males and 20 females; median age, 62.5 years), who had been hospitalized with bilateral pneumonia, 60% with one or more comorbidities. IgG antibodies binding to SARS-CoV-2 RBD were measured by ELISA. SARS-CoV-2-reactive CD69<sup>+</sup>-expressing-IFNγ-producing-CD4<sup>+</sup> and CD8<sup>+</sup> T cells were enumerated in heparinized whole blood by flow cytometry for ICS. **Results**: Detectable SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>-IFN-γ CD4<sup>+</sup> and CD8<sup>+</sup> T cells were displayed in 17 (29.3%) and 6 (10.3%) subjects respectively, at a median of 84 days after onset of symptoms (range, 58-191 days). Concurrent comorbidities increased the risk (OR, 3.15; 95% CI, 1.03-9.61; P=0.04) of undetectable T-cell responses in models adjusted for age, sex and hospitalization ward. Twenty-one out of the 35 patients (60%) had detectable RBD-specific serum IgGs at a median of 118 days (range, 60 to 145 days) after symptoms onset. SARS-CoV-2 RBD-specific IgG serum levels were found to drop significantly over time. Conclusion: A relatively limited number of subjects who developed severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFNy CD4<sup>+</sup> and CD8<sup>+</sup> T cells at midterm after clinical diagnosis. Our data also indicated that serum levels of RBD-

specific IgGs decline over time, becoming undetectable in some patients.

**KEY WORDS:** SARS-CoV-2, COVID-19, T cells, Receptor Binding Domain-specific

51 IgG antibodies.

50

52

# INTRODUCTION

53 Experimental evidence supports a major role of neutralizing antibodies (NtAb) and 54 skewed Th1 functional immune responses in preventing and controlling SARS-CoV-2 55 infection [1-4]. Epitopes eliciting NtAb have been mapped within all SARS-CoV-2 56 structural proteins; among these, NtAbs targeting the receptor binding domain (RBD) of 57 the viral spike protein (S) appear to display maximum specificity and potency [5-7]. 58 Broad specificity to structural and non-structural proteins has been reported across 59 SARS-CoV-2-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells, of which S, membrane (M) and 60 nucleocapsid (N) proteins are immunodominant in most individuals [8-18]. Both SARS-61 CoV-2-specific NtAb and T cells are readily detectable in a large proportion of acute or 62 short-term convalescent COVID-19 patients [8-18], although the strength of adaptive 63 immune responses may be modulated by the severity of the disease [1-4]. Data on 64 SARS-CoV infection suggest that memory B and T cells have a potential for long-65 lasting persistence (over years) [19,20], yet the durability of SARS-CoV-2 adaptive 66 immunity remains to be established. Determining whether SARS-CoV-2 B- and T-cell 67 responses persist over time following natural infection or after vaccination seems of 68 paramount relevance in designing effective public health policies to prevent virus 69 transmission and spread. In the current study we enumerated SARS-CoV-2-reactive 70 CD4<sup>+</sup> and CD8<sup>+</sup> T cells targeting S and M proteins, and measured IgG antibodies 71 binding to RBD of S protein, along a timeframe of up to 6 months after symptoms onset 72 in a cohort of recovered COVID-19 patients who had been hospitalized due to severe 73 clinical forms of the disease.

## PATIENTS AND METHODS

74

75 **Patients and specimens** 76 A total of 58 non-consecutive patients (38 males and 20 females; median age, 62.5 77 years; range, 27 to 82 years) were recruited at the COVID-19 follow-up unit of Hospital 78 Clínico Universitario of Valencia, at a median of 85 days (range, 58 to 191 days) after 79 onset of COVID-19 symptoms. SARS-CoV-2 infection was diagnosed by RT-PCR 80 (between February 26 and May 16) [21]. The only patient inclusion criterion was the 81 availability of serum and/or whole blood specimens for B- and T-cell immunity 82 analyses described below. Medical history and laboratory data were retrospectively 83 reviewed. Clinical severity of COVID-19 was graded following World Health 84 Organization criteria [22]. Whole blood was also collected from seven non-SARS-CoV-85 2-exposed healthy individuals (up to March 2020) who served as controls. The current study was approved by the Research Ethics Committee of Hospital Clínico 86 87 Universitario INCLIVA (March 2020). 88 SARS-CoV-2 RBD IgG immunoassay 89 IgG antibodies binding to SARS-CoV-2 RBD made in Sf9 cells infected with 90 recombinant baculoviruses (Invitrogen, CA, USA) were measured by an enzyme-linked 91 immunosorbent assay (ELISA) as previously described [23]. 92 SARS-CoV-2-reactive IFN-γ CD4<sup>+</sup> and CD8<sup>+</sup> T cells 93 SARS-CoV-2-reactive CD69<sup>+</sup>-expressing-IFNγ-producing-CD4<sup>+</sup> and CD8<sup>+</sup> T cells were 94 enumerated in heparinized whole blood by flow cytometry for intracellular cytokine 95 staining (ICS) (BD Fastimmune, BD Biosciences, San Jose, CA, USA) as previously 96 described [21]. Two sets of 15-mer overlapping peptides (11 mer overlap) 97 encompassing the SARS-CoV-2 Spike glycoprotein N-terminal 1-643 amino acid

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

sequence (158 peptides) and the entire sequence of SARS-CoV-2 M protein (53 peptides), were used in combination for stimulation ( $1 \square \mu g/ml$  per peptide) during 6 h, in the presence of CD28 and CD49d costimulatory mAbs and brefeldin A (10µg/ml), the latter after two hour incubation. Peptide mixes were obtained from JPT Peptide Technologies GmbH (Berlin, Germany). The appropriate positive (phytohemagglutinin) and isotype controls were used. The total number of SARS-CoV-2-reactive CD8<sup>+</sup> T cells was calculated by multiplying the percentages of CD4<sup>+</sup> or CD8<sup>+</sup> T cells producing IFNγ on stimulation (after background subtraction) by the absolute CD4<sup>+</sup> or CD8<sup>+</sup> Tcell counts. Responses  $\geq 0.1\%$  were considered specific [21]. **Laboratory measurements** Clinical laboratory investigation included serum levels IL-6, ferritin and Dimer-D, which were monitored at least twice weekly during hospital stay. **Statistical methods** Frequency comparisons for categorical variables were carried out using the Fisher exact test. Differences between medians were compared using the Mann-Whitney U-test. The Spearman's rank test was used for analysis of correlation between continuous variables. For logistic regression analyses, variables with P values <0.1 in univariate models were included in multivariate models. Two-sided exact P-values were reported. A P-value <0.05 was considered statistically significant. The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). **RESULTS Patient clinical features** 

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

All 58 patients in this cohort developed severe forms of COVID-19 requiring hospitalization either in the intensive care unit (ICU) (n=21) or in other hospital wards (n=37). All patients presented with bilateral pneumonia and 60% had one or more comorbidities, including diabetes mellitus, asthma, hypertension, dyslipidemia, cancer or chronic lung disease. All ICU patients underwent mechanical ventilation. Median hospitalization of patients was 16 days (range, 6-61 days). Patients in the two groups were matched for age, sex and comorbidities (not shown). SARS-CoV-2-reactive IFN-7 CD4<sup>+</sup> and CD8<sup>+</sup> T cells in recovered COVID-19 patients SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>-IFN-γ CD4<sup>+</sup> and CD8<sup>+</sup> T cells were enumerated at a median of 84 days after symptoms onset (range, 58-191 days). Representative plots are shown in Supplementary Figure 1. Of the 58 patients, 17 (29.3%) and 6 (10.3%) had detectable SARS-CoV-2 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses, respectively. Only two patients displayed both SARS-CoV-2-reactive T-cell subsets. SARS-CoV-2 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts ranged from 0.98 to 43.75 cells/µL, and from 0.48 to 2.98 cells/µL, respectively (median, 4.83 and 1.13 cells/µL, respectively). Figure 1A shows SARS-CoV-2 T-cell reactivity according to the sampling timeframe after symptoms onset (arbitrarily categorized as 2-3 months vs. > 3 months). Overall, we found no difference between the percentage of patients with or without detectable CD4<sup>+</sup> (P=0.40) or CD8<sup>+</sup> (P=0.12) T cells across comparison groups; nevertheless, none of the patients sampled beyond day 130 after COVID-19 presentation (n=3) exhibited either SARS-CoV-2 CD4<sup>+</sup> or CD8<sup>+</sup> T-cell responses. Of note, patients with or without detectable SARS-CoV-2-reactive T cells were monitored within a comparable

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

timeframe (median, 91 days; range, 60 to 118 days vs. median 83 days, range, 58 to 191 days; P=0.18). SARS-CoV-2 RBD-specific IgGs in recovered COVID-19 patients Serum specimens for quantitation of SARS-CoV-2 RBD-specific IgGs were available from 35 patients, and collected at a median of 118 days (range, 60 to 145 days) from onset of symptoms. Twenty-one of the 35 patients (60%) had detectable RBD-specific IgGs (median, 1.8 AU/mL; range, 0.99-4.14 AU/mL). RBD-specific IgG reactivity according to time of sampling (2-3 months vs. >3 months) is shown in Figure 1B. A comparable number of patients had detectable responses at both time points (P=0.84). Out of the 21 patients exhibiting RBD-specific IgG reactivity, 10 (47.6%) had measurable SARS-CoV-2 T-cell responses (CD4<sup>+</sup> T cells in 6 patients and CD8<sup>+</sup> T cells in the remainder). Of the 14 patients lacking RBD-specific IgGs, 5 had detectable SARS-CoV-2 CD4<sup>+</sup> T cells and none had SARS-CoV-2 CD8<sup>+</sup> T cells. Eighteen of the 35 patients had paired serum samples collected at the time of hospitalization (median, 22 days after symptoms onset; range, 8-34 days) and after recovery (median, 120 days after symptoms onset; range 93-145 days); paired specimens were analyzed in parallel. SARS-CoV-2 RBD-specific IgGs were detectable in 17 patients at the first time point and 14 at the latter. As shown in Figure 2, SARS-CoV-2 RBD-specific IgG serum levels were found to drop significantly over time (from a median of 4.97 AU/ml to a median of 1.51 AU/ml; P<0.001). Finally, we found no correlation between SARS-CoV-2 RBD-specific IgG levels and SARS-CoV-2 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts (P=0.12 and P=0.14, respectively) in recovered COVID-19 patients.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

Demographic, clinical and biological factors associated with detectable SARS-CoV-2-reactive T cells or RBD-specific IgGs in recovered COVID-19 patients The detection rate of SARS-CoV-2-reactive T cells (either CD4<sup>+</sup>, CD8<sup>+</sup> or both) was comparable across patients admitted to ICU or other medical wards (P=0.82) (Table 1). Likewise, both median SARS-CoV-2 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts were similar between groups (Figure 3). Neither age nor sex was found to influence either the likelihood (Table 1) or magnitude (Figure 2) of detectable SARS-CoV-2 T-cell responses. In contrast, patients displaying one or more comorbidities were significantly (P=0.04) less likely to exhibit detectable T-cell responses (Table 1), although median Tcell counts were not significantly dissimilar across comparison groups (Figure 3). In fact, comorbidities increased the risk (OR, 3.15; 95% CI, 1.03-9.61; P=0.04) of undetectable T-cell responses in logistic regression models adjusted for age, sex and hospitalization ward (ICU vs. others). The likelihood of detecting SARS-CoV-2-RBD-specific IgGs was not influenced by age (P=0.67), or presence of comorbidities (P=0.65), but was higher in males (P=0.004) and in ICU patients (P=0.019) (Table 1). Both factors were found to increase the likelihood of detecting an antibody response in multivariate models adjusted for age and comorbidities (OR, 11.71; 95% CI, 1.86-73.7; P=0.009 and OR, 6.57; 95% CI, 1.04-41.4; P=0.04, respectively). Nevertheless, neither of these parameters had a significant impact on serum SARS-CoV-2 IgG levels (not shown). The net state of inflammation shortly after viral infections may shape the quality and strength of ongoing adaptive immunity responses [24]. In this context, we next compared serum peak levels of several inflammatory biomarkers, including IL-6, ferritin and Dimer-D, measured within the first 15 days after hospitalization among recovered COVID-19 patients with or without detectable SARS-CoV-2 T-cell responses. As shown in Figure 4, no significant differences were found between comparison groups for any of these parameters. A similar observation was made for SARS-RBD-specific IgGs (not shown). Furthermore, was observed either weak or no correlation between serum peak levels of IL-6, ferritin or Dimer-D and SARS-CoV-2 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts or SARS-CoV-2 RBD-specific IgG levels (Supplementary Table 1).

## **DISCUSSION**

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

A large body of evidence has accumulated on the features of SARS-CoV-2-specific adaptive immunity in patients who recovered from mild or severe clinical forms of COVID-19 [1-4,8-18,23]. To our knowledge, these studies mostly involved recently recovered patients (up to 3 months from onset of symptoms), of whom a large percentage (45-95%) consistently exhibited both T- and B-cell responses. The dynamics of such immune responses beyond this time point remains largely unexplored. Elucidating whether SARS-CoV-2-targeted T- and B-cell responses persist over time following natural infection, and if so for how long, is of paramount relevance from a clinical and public health perspective, mainly because it may allow us to predict susceptibility to reinfections upon re-exposure. The key issue to resolve is whether SARS-CoV-2 T- and B-cell memory responses are durable (over years), as may occur following SARS-CoV infection [19,20], or instead wane over a short period until undetectable, as seen in seasonal coronavirus infections [20]. Here, we assessed SARS-CoV-2 T- and B-cell immune responses in patients who had recovered from severe COVID-19 at medium term (from 2 to 6 months) after disease presentation. We used a whole blood flow cytometry ICS method for detection and

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

enumeration of activated and functional (IFN-γ-producing) SARS-CoV-2-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells, targeting the S1 region of the S protein and the M protein. Both proteins contain highly immunodominant HLA-I and HLA-II restricted epitopes eliciting readily detectable activated and/or functional T cells (CD4<sup>+</sup> T cells more frequently), in most convalescent or short-term recovered COVID-19 patients [10-18]. Like other SARS-CoV-2 T-cell immunoassays [11,12,14,15], our ICS assay appears capable of quantifying coronavirus cross-reactive T cells, as two out of seven nonexposed individuals exhibited detectable responses (not shown). Likewise, RBD-specific IgG levels strongly correlate with NtAb titers as measured using live or S-pseudotyped SARS-CoV-2, so they can be used as a proxy for inferring the neutralizing activity of sera [6,7,23]. Several major findings arose from our study. First, SARS-CoV-2-S1/M-reactive-IFN-γ CD4<sup>+</sup> and CD8<sup>+</sup> T cells were detected in a limited number of recovered patients from severe COVID-19 (around 30% and 10% for CD4<sup>+</sup> and CD8<sup>+</sup> T cells, respectively). Furthermore, we were unable to document SARS-CoV-2 T-cell reactivity beyond day 130 after COVID-19 diagnosis. This latter observation must be interpreted with caution given the low number of patients (n=3) tested within that timeframe. In a previous study also recruiting severe COVID-19 patients [21], we reported that around 40% of patients were capable of mounting SARS-CoV-2-S1/M-reactive IFN-γ-producing CD8<sup>+</sup> T cell responses shortly after infection (median, 27 days after symptoms onset); in that study, SARS-CoV-2-reactive CD4<sup>+</sup> T cell responses were not assessed. Nevertheless, other studies including hospitalized COVID-19 patients [11,12] found detectable functional CD4<sup>+</sup> T-cell responses to both S1 and M proteins in a large fraction of patients either during the acute phase of the disease or at short-term convalescence. Taken collectively, the above observations suggest that functional SARS-CoV-2-S1/M-reactive T-cell

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

frequencies in peripheral blood may wane over time. If confirmed in further studies, this phenomenon may be associated with COVID-19 severity. In this sense it has been postulated that exuberant or aberrant activation of the innate immune system upon encounter with SARS-CoV-2, resulting in suboptimal expansion of functional T cells, may be a hallmark in patients developing the severest forms of COVID-19 [1,25]. In support of this assumption, around 60% of individuals who had experienced mild forms of the disease were shown to display S1 and M-reactive T-cell responses by 6 months after COVID-19 diagnosis [26]. Likewise, Dan et al. [27] reported that SARS-CoV-2-(both S and M)-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells declined over time, with a half-life of 3-5 months in a cohort (n=41) skewed toward mild forms of COVID-19, although they remained detectable in many subjects at more than 6 months after COVID-19 diagnosis. Second, in the current series, 60% of individuals displayed detectable SARS-CoV-2-RBD-specific IgGs at 2-5 months following COVID-19 diagnosis. In this context, it has been consistently reported that RBD IgG seroconversion occurs almost universally in moderate to severe COVID-19 patients within 3-4 weeks after onset of symptoms [6,7,22]. The above data thus suggest that the likelihood of detecting such antibody specificity in sera diminishes over time. Moreover, by analyzing paired serum specimens collected within the first month after symptoms onset and by 3-5 months after COVID-19 diagnosis in recovered individuals, we showed that the detection rate decreased slightly (from 94% to 77%) over time, as was the case of SARS-CoV-2-RBD-specific serum IgG levels. Third, we found no correlation between SARS-CoV-2-reactive IFN-γ CD4<sup>+</sup> T cells and RBD-specific antibody levels, suggesting that SARS-CoV-2 T- and B-cell responses may follow divergent kinetics, and perhaps that CD4<sup>+</sup> T-cell help is not strictly required to sustain SARS-CoV-2-RBD-specific IgG responses over the medium term, at least in

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

the population group analyzed herein. Other studies [10,28] found a strong correlation between NtAb antibody titers and the numbers of virus-specific T cells targeting S or N proteins in short-term convalescent individuals. Fourth, frequency and logistic regression analyses identified presence of one or more comorbidities, but not age, sex or COVID-19 severity (ICU vs. non-ICU), as a factor presumably hampering the persistence of peripheral blood SARS-CoV-2-S1/M-reactive T cells in recovered COVID-19 patients. As for RBD IgGs, both sex (male) and COVID-19 severity appeared to increase the probability of detectable responses at medium term after disease presentation, although neither of these had an impact on RBD IgG levels. Fifth, since uncontrolled inflammation driven by innate immune response shortly following viral infection may negatively affect the strength and durability of arising Tcell responses [23], we investigated whether serum peak levels of inflammatory biomarkers (IL-6, Dimer-D and ferritin) measured early after COVID-19 presentation (within 15 days) differed across recovered COVID-19 patients with or without detectable SARS-CoV-2-reactive T cells or SARS-COV-2-RBG IgGs, finding no variation. Moreover, little or no correlation was observed between the magnitude of systemic inflammation and SARS-CoV-2 immune parameters. The current study has several limitations that must be acknowledged; predominantly, the reduced cohort size. Second, T-cell immunity analyses were conducted at a single time point. We cannot rule out that detectability of the two SARS-CoV-2-reactive T cells by the immunoassay used herein may fluctuate over time. Moreover, no whole blood specimens drawn at the time of patient hospitalization were available for T-cell immunity assessment. Third, T cells and antibodies targeting other antigen specificities,

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

which may afford protection against SARS-CoV-2, were not evaluated. Fourth, T-cell functionalities other than IFN-y production upon antigenic stimulation were not explored. Fifth, we cannot be certain whether our whole blood T-cell immunoassay might be less sensitive than others using fresh or cryopreserved isolated PBMCs. Sixth, taking serum peak levels of IL-6, Dimer-D and ferritin during the first 15 days after symptoms onset is an admittedly arbitrary time point for analyses which may not have captured the true net state of systemic inflammation generated shortly after SARS-CoV-2 infection. In summary, we have shown that a relatively low number of subjects who developed severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFNy CD4<sup>+</sup> and CD8<sup>+</sup> T cells at medium term after clinical diagnosis (up to 6 months), particularly those with concurrent comorbidities. Our data also indicated that serum levels of RBD-specific IgGs decline over time, becoming undetectable in some patients. Elucidating whether individuals lacking these specific adaptive immune responses are susceptible to reinfection is beyond the scope of the current study and needs to be addressed in future research. ACKNOWLEDGMENTS We thank all personnel working at Clinic University Hospital for their unwavering commitment in the fight against COVID-19. FINANCIAL SUPPORT This work received no public or private funds. CONFLICTS OF INTEREST The authors declare no conflicts of interest.

## **AUTHOR CONTRIBUTIONS**

- 312 BO, EA, IT, PA, MJR and RG-R: Methodology and data validation. BO, EA, IT:
- 313 Formal analysis. JR-D, JB, DN: Conceptualization, supervision. MLB, JR and JS-C:
- 314 Clinical Staff in charge of patients. DN: writing the original draft. All authors reviewed
- and approved the original draft.

# 316 **REFERENCES**

311

- 317 1. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune
- 318 Response During SARS-CoV-2 Infection: Lessons From the Past. Front Immunol
- 319 2020;11:1949.
- 320 2. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat
- 321 Rev Immunol 2020;20:392-394.
- 322 3. de Candia P, Prattichizzo F, Garavelli S, Matarese G. T Cells: Warriors of SARS-
- 323 CoV-2 Infection. Trends Immunol 2020; S1471-4906(20)30260-X.
- 4. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-
- 325 CoV: Implications for vaccine development against MERS-CoV. Antiviral Res
- 326 2017;137:82-92.
- 5. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent
- 328 SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal
- 329 model. Science 2020; 369:956-963.
- 330 6. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et
- 331 al. The receptor binding domain of the viral spike protein is an immunodominant and
- 332 highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol
- 333 2020;5:eabc8413.

- 334 7. Barnes CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman
- 335 PR, et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal
- 336 Common Epitopes and Recurrent Features of Antibodies. Cell 2020; S0092-
- 337 8674(20)30757-1.
- 338 8. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.
- 339 Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with
- acute respiratory distress syndrome. Sci Immunol. 2020;5:eabd2071.
- 9. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
- 342 Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and
- associations with age and disease severity. Cell 2020;183:1–17.
- 344 10. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-
- 345 2-specific humoral and cellular immunity in COVID-19 convalescent
- 346 individuals. Immunity 2020;52:971–977.
- 347 11. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al.
- 348 Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19
- disease and unexposed individuals. Cell 2020;181:1489–1501.
- 350 12. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
- reactive T cells in healthy donors and patients with COVID-19. Nature 587:270-274.
- 352 13. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, et
- 353 al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2
- 354 proteins is not associated with recovery in critical COVID-19 Patients. Cell Rep
- 355 Med 2020; 1:100092...
- 356 14. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-
- 357 CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
- 358 controls. Nature 2020;584:457–462.

- 359 15. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and
- 360 cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370:89-94.
- 361 16. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev
- 362 Immunol 2020;20:529-536.
- 363 17. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al.
- 364 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
- 365 COVID-19. Cell 2020;183:158-168.e14.
- 366 18. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al.
- 367 Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
- 368 Cell 2020; S0092-8674(20)31565-8.
- 369 19. Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan YJ. Memory T cell
- 370 responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine
- 371 2016;34:2008–2014.
- 372 20. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: specificity, function,
- durability, and role in protection. Sci Immunol 2020;5:eabd6160.
- 374 21. Giménez E, Albert E, Torres I, Remigia MJ, Alcaraz MJ, Galindo MJ, et al. SARS-
- 375 CoV-2-reactive interferon-γ-producing CD8+ T cells in patients hospitalized with
- 376 coronavirus disease 2019. J Med Virol. 2020 Jun 24:10.1002/jmv.26213.
- 22. Clinical Management of COVID-19. WHO/2019-nCoV/clinical/2020.5
- 378 23. Gozalbo-Rovira R, Gimenez E, Latorre V, Francés-Gómez C, Albert E, Buesa J, et
- 379 al. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of
- hospitalized COVID-19 patients. J Clin Virol 2020;131:10461.
- 381 24. Condotta SA, Richer MJ. The immune battlefield: The impact of inflammatory
- cytokines on CD8+ T-cell immunity. PLoS Pathog 2017;13:e1006618.

- 383 25. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2
- 384 following natural infection and vaccination. Biochem Biophys Res Commun 2020;
- 385 S0006-291X(20)31983-5
- 386 26. Breton G, Mendoza P, Hagglof T, Oliveira TY, Schaefer-Babajew D, Gaebler C, et
- 387 al. Persistent Cellular Immunity to SARS-CoV-2 Infection. BiorXiv 2020;
- 388 https://doi.org/10.1101/2020.12.08.416636.
- 27. Dan JM, Mateus J, Kato Y, Hastie KM, Faliti CE, Ramirez SI, et al. Immunological
- 390 memory to SARS-CoV-2 assessed for greater than six months after infection. BiorXiv
- 391 2020; doi: https://doi.org/10.1101/2020.11.15.383323.
- 392 28 Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory
- 393 CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals
- 394 following COVID-19. Nat Immunol 2020;21:1336-1345.
- 396 FIGURE LEGENDS

- 397 **Figure 1.** SARS-CoV-2 T- and B-cell responses in individuals recovered from severe
- 398 COVID-19. Peripheral blood SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>-expressing IFN-γ-
- 399 producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells (A) and SARS-CoV-2-RBD-specific IgG levels (B)
- 400 according to the time of sampling following symptoms onset. Bars indicate median
- 401 levels. *P* values are shown.
- 402 **Figure 2**. Kinetics of SARS-CoV-2-RBD-specific IgG levels in individuals recovered
- 403 from severe COVID-19. Serum levels of such an antibody specificity were measured at
- 404 the time of hospitalization (acute COVID-19) and 2-5 months afterwards (recovered
- 405 COVID-19). *P* value is shown.

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

Figure 3. Impact of demographics, hospitalization ward and comorbidities on peripheral blood SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>-expressing IFN-γ-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells in subjects recovered from severe COVID-19. Bars indicate median levels. P values are shown. **Figure 4.** Serum peak levels of inflammatory biomarkers (IL-6, Ferritin and Dimer-D) measured within the first 15 days after hospitalization and SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>-expressing IFN-γ-producing CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts in subjects who recovered from severe COVID-19. Bars indicate median levels. P values are shown. **Supplementary Figure 1.** Enumeration of SARS-CoV-2-S1/M-reactive CD69<sup>+</sup>expressing IFN-γ-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells by flow cytometry for intracellular staining in COVID-19 patients. (a) Lymphocyte gating; (b) CD3<sup>+</sup> gating; CD8<sup>+</sup> gating; (d) CD3<sup>+</sup>/CD69<sup>+</sup>/IFN-γCD8<sup>+</sup>/Isotype control; (e-f) CD3<sup>+</sup>/CD69<sup>+</sup>/IFN-γCD8<sup>+</sup> positive individual; (g-h) CD3<sup>+</sup>/CD69<sup>+</sup>/IFN-γCD8<sup>+</sup> negative individual. Dot-plot figures were built with FlowJo software (BD Biosciences).







